28.04.2019, 1076 Zeichen

Marinomed: Stock quoted biotech company Marinomed Biotech AG has announced the successful completion of the pivotal Phase III study for Budesolv. The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose. The planned primary endpoint of the study for the first product of the innovative Marinosolv® technology platform has thus been achieved. The approval process can be continued as scheduled. As announced, the complete Phase III study with detailed results is expected and will be published by the end of the second quarter of 2019 at the latest.Marinomed has succeeded in increasing the bioavailability of hardly soluble compounds to treat sensitive tissues such as nose and eyes via the Marinosolv® technology platform. The platform's flagship product is Budesolv, a nasal spray for the treatment of allergic rhinitis.
Marinomed Biotech: weekly performance: -0.62%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/04/2019)

Christian Drastil: Wiener Börse Plausch

Kapitalmarkt-stimme.at daily voice: Wisst ihr, was der ATX TR gestern gemacht hat? Ein neues All-time-High (und diese Aktien sind hot)

Bildnachweis

Aktien auf dem Radar:Rosenbauer, RBI, DO&CO, Semperit, Austriacard Holdings AG, EuroTeleSites AG, Porr, Amag, Andritz, AT&S, VIG, Uniqa, Palfinger, Polytec Group, Marinomed Biotech, OMV, Addiko Bank, Erste Group, Flughafen Wien, Lenzing, Mayr-Melnhof, RWT AG, Strabag, Wienerberger, BKS Bank Stamm, BTV AG, Oberbank AG Stamm, CA Immo, CPI Europe AG, Österreichische Post, Telekom Austria.

---